Fresh Tracks Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Bert Marchio

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	3.3yrs
CEO ownership	n/a
Management average tenure	2.4yrs
Board average tenure	2.2yrs

Recent management updates

Recent updates

CEO

Bert Marchio (71 yo)

3.3yrs

Tenure

Mr. Albert Nicholas Marchio, II, also known as Bert, serves as Chief Financial Officer at Fresh Tracks Therapeutics, Inc. since December 1, 2020 and serves as its CEO, Secretary, Chairman since October 02,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Albert Marchio	CEO, CFO	3.3yrs	no data	no data
Aaron Fox-Collis	VP of Finance & Chief Accounting Officer	1.2yrs	no data	0% € 0
Aron Aizenstat	Vice President of Corporate Development & Operations	no data	no data	no data
Sue Fattor	Head of Human Resource	2.9yrs	no data	no data
James McElvain	Interim Head of CMC Development	1.9yrs	no data	no data

2.4yrs

Average Tenure

Experienced Management: VCC's management team is considered experienced (2.4 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Albert Marchio	CEO, CFO	less than a year	no data	no data
Katherine Fitzgerald	Member of Scientific Advisory Board	2.2yrs	no data	no data
Peter Nigrovic	Member of Scientific Advisory Board	2.2yrs	no data	no data
Pui Lee	Member of Scientific Advisory Board	2.2yrs	no data	no data
Bernard Khor	Member of Scientific Advisory Board	2.2yrs	no data	no data
Bridget Wagner	Member of Scientific Advisory Board	2.2yrs	no data	no data

2.2yrs

Average Tenure

Experienced Board: VCC's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.

Fresh Tracks Therapeutics Management

Management criteria checks 1/4

Key information

Recent management updates

Fresh Tracks Therapeutics, Inc. Announces Executive Changes

Fresh Tracks Therapeutics, Inc. Announces Resignation of Robert B. Brown from the Board of Directors, Effective Immediately

Fresh Tracks Therapeutics, Inc. Announces Executive Changes, Effective February 1, 2023

Insufficient new directors

Fresh Tracks Therapeutics Appoints Deepak Chadha to the Additional Position of Chief Operating Officer

Insufficient new directors

Recent updates

Fresh Tracks Therapeutics, Inc. Files Form 15

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from S&P TMI Index

Fresh Tracks Therapeutics, Inc.(OTCPK:FRTX) dropped from NASDAQ Composite Index

Fresh Tracks Therapeutics Announces Its Common Stock to Be Suspended from Trading on Nasdaq At Open of Business on December 19, 2023

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics' Common Stock To Be Delisted from Nasdaq

Fresh Tracks Therapeutics, Inc. Announces Executive Changes

New minor risk - Revenue size

Second quarter 2023 earnings released: US$0.39 loss per share (vs US$0.43 loss in 2Q 2022)

Fresh Tracks Therapeutics, Inc. Announces Resignation of Robert B. Brown from the Board of Directors, Effective Immediately

First quarter 2023 earnings released: US$1.14 loss per share (vs US$3.55 loss in 1Q 2022)

Full year 2022 earnings released: US$7.52 loss per share (vs US$22.12 loss in FY 2021)

Fresh Tracks Therapeutics, Inc. Announces Executive Changes, Effective February 1, 2023

Fresh Tracks Therapeutics, Inc. Announces Publication of Preclinical Data for FRTX-02

Third quarter 2022 earnings released: US$2.07 loss per share (vs US$7.15 loss in 3Q 2021)

Insufficient new directors

Fresh Tracks Therapeutics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Fresh Tracks Therapeutics Appoints Deepak Chadha to the Additional Position of Chief Operating Officer

Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of Dyrk1a Inhibitor FRTX-02

Insufficient new directors

Brickell Biotech Receives Notice from the Nasdaq Stock Market in Relation to Non-Compliance with the Independent Director and Audit Committee Requirements

Second quarter 2022 earnings released: US$0.01 loss per share (vs US$7.29 loss in 2Q 2021)

Brickell Biotech, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Brickell Biotech, Inc. Announces Resignation of Dennison T. Veru from the Board of Directors

Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

Brickell Biotech Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market

Brickell Biotech, Inc. Announces Executive Changes

Brickell Biotech Doses First Subject in Phase 1 Study of DYRK1A Inhibitor BBI-02

First quarter 2022 earnings released: US$0.079 loss per share (vs US$0.15 loss in 1Q 2021)

Brickell Biotech, Inc. to Report Q1, 2022 Results on May 12, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Third quarter 2021 earnings released: US$0.16 loss per share (vs US$0.15 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.16 loss per share (vs US$0.43 loss in 2Q 2020)

Co-Founder & Chairman of the Board recently bought €113k worth of stock

Brickell Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $7 million.

Brickell Biotech, Inc. Announces Final Patient Completed in First U.S. Phase 3 Pivotal Clinical Study and Patient Enrollment Completed in Second U.S. Phase 3 Pivotal Clinical Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech Announces Initiation of A Phase 1 Study of Sofpironium Bromide Gel in Primary Palmoplantar Hyperhidrosis Patients by Its Development Partner, Kaken Pharmaceutical in Japan

Brickell Biotech Receives A Notice from Listing Qualifications Department of Nasdaq Stock Market

Brickell Biotech, Inc. Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.45 loss in 1Q 2020)

Forecast to breakeven in 2025

Brickell Biotech Completes Patient Enrollment in U.S. Phase 3 Pivotal Cardigan I Study of Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

CEO & Director recently bought €99k worth of stock

Brickell Biotech, Inc., Annual General Meeting, Apr 19, 2021

Full year 2020 earnings released: US$0.85 loss per share (vs US$4.50 loss in FY 2019)

Revenue misses expectations

Brickell Biotech, Inc. to Report Q4, 2020 Results on Mar 09, 2021

New 90-day high: €1.36

Brickell Biotech, Inc. Announces Publication of Japan Pivotal Phase 3 Study Results for Sofpironium Bromide Gel, 5% (Ecclock®)

New 90-day high: €0.90

Brickell Biotech, Inc. Doses First Patient in Second U.S. Pivotal Phase 3 Clinical Study

Brickell Biotech, Inc. Announces Management Changes

Third quarter 2020 earnings released: US$0.15 loss per share

Brickell Biotech, Inc. to Report Q3, 2020 Results on Nov 12, 2020

New 90-day high: €0.91

Brickell Biotech, Inc. Announces Initiation of U.S. Phase 3 Program Evaluating Sofpironium Bromide Gel, 15% for the Treatment of Primary Axillary Hyperhidrosis

Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis

New 90-day low - €0.65

New 90-day low - €0.67

First half earnings released

Brickell Biotech, Inc. to Report Q2, 2020 Results on Aug 12, 2020

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure